Identification and Validation of Ferroptosis-related LncRNA Signature As a Prognostic Model for Skin Cutaneous Melanoma

Overview

Journal Front Immunol

Specialty Allergy & Immunology

Date 2022 Oct 17

PMID 36248853

Authors

Sen Guo

Jianru Chen

Xiuli Yi

Zifan Lu

Weinan Guo

Affiliations

Soon will be listed here.

Abstract

Background: Melanoma is a type of skin cancer, which originates from the malignant transformation of epidermal melanocytes, with extremely high lethality. Ferroptosis has been documented to be highly related to cancer pathogenesis and the effect of immunotherapy. In addition, the dysregulation of lncRNAs is greatly implicated in melanoma progression and ferroptosis regulation. However, the significance of ferroptosis-related lncRNA in melanoma treatment and the prognosis of melanoma patients remains elusive.

Methods: Least Absolute Shrinkage Selection Operator (LASSO) regression analysis in the TCGA SKCM database, a cutaneous melanoma risk model was established based on differentially-expressed ferroptosis-related lncRNAs (DEfrlncRNAs). The nomogram, receiver operating characteristic (ROC) curves, and calibration plots were conducted to examine the predictive performance of this model. Sequentially, we continued to analyze the differences between the high- and low-risk groups, in terms of clinical characteristics, immune cell infiltration, immune-related functions, and chemotherapy drug sensitivity. Moreover, the expressions of DEfrlncRNAs, PD-L1, and CD8 were also examined by qRT-PCR and immunohistochemical staining in melanoma tissues to further confirm the potential clinical implication of DEfrlncRNAs in melanoma immunotherapy.

Results: 16 DEfrlncRNAs were identified, and a representative risk score for patient survival was constructed based on these 16 genes. The risk score was found to be an independent prognostic factor for the survival of melanoma patients. In addition, the low-risk group of patients had higher immune cell infiltration in the melanoma lesions, higher sensitivity to chemotherapeutic agents, and a better survival prognosis. Besides, the high expression of the identified 5 DEfrlncRNA in the low-risk group might suggest a higher possibility to benefit from immune checkpoint blockade therapy in the treatment of melanoma.

Conclusion: The DEfrlncRNA risk prediction model related to ferroptosis genes can independently predict the prognosis of patients with melanoma and provide a basis for evaluating the response of clinical treatment in melanoma.

Citing Articles

The Role of Non-coding RNAs in Tumorigenesis, Diagnosis/Prognosis, and Therapeutic Strategies for Cutaneous Melanoma.

Schaft N, Dorrie J Methods Mol Biol. 2024; 2883:79-107.

PMID: 39702705 DOI: 10.1007/978-1-0716-4290-0_4.

Combined signature of G protein-coupled receptors and tumor microenvironment provides a prognostic and therapeutic biomarker for skin cutaneous melanoma.

Song B, Wang K, Peng Y, Zhu Y, Cui Z, Chen L J Cancer Res Clin Oncol. 2023; 149(20):18135-18160.

PMID: 38006451 DOI: 10.1007/s00432-023-05486-4.

Integrated analysis reveals SMARCD1 is a potential biomarker and therapeutic target in skin cutaneous melanoma.

Chen J, Yu N, Ou S, Wang X, Li H, Zhu H J Cancer Res Clin Oncol. 2023; 149(13):11619-11634.

PMID: 37401939 DOI: 10.1007/s00432-023-05064-8.

Machine learning-based signature of necrosis-associated lncRNAs for prognostic and immunotherapy response prediction in cutaneous melanoma and tumor immune landscape characterization.

Cui Z, Liang Z, Song B, Zhu Y, Chen G, Gu Y Front Endocrinol (Lausanne). 2023; 14:1180732.

PMID: 37229449 PMC: 10203625. DOI: 10.3389/fendo.2023.1180732.

Development and validation of ferroptosis-related lncRNA signature and immune-related gene signature for predicting the prognosis of cutaneous melanoma patients.

Xiong K, Wang Z, Houssou Hounye A, Peng L, Zhang J, Qi M Apoptosis. 2023; 28(5-6):840-859.

PMID: 36964478 DOI: 10.1007/s10495-023-01831-7.

References

Perez M, Magtanong L, Dixon S, Watts J . Dietary Lipids Induce Ferroptosis in Caenorhabditiselegans and Human Cancer Cells. Dev Cell. 2020; 54(4):447-454.e4. PMC: 7483868. DOI: 10.1016/j.devcel.2020.06.019. View

Friedman J, Hastie T, Tibshirani R . Regularization Paths for Generalized Linear Models via Coordinate Descent. J Stat Softw. 2010; 33(1):1-22. PMC: 2929880. View

Gutzmer R, Stroyakovskiy D, Gogas H, Robert C, Lewis K, Protsenko S . Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAF mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2020; 395(10240):1835-1844. DOI: 10.1016/S0140-6736(20)30934-X. View

Liu R, Yang F, Yin J, Liu Y, Zhang W, Zhou H . Influence of Tumor Immune Infiltration on Immune Checkpoint Inhibitor Therapeutic Efficacy: A Computational Retrospective Study. Front Immunol. 2021; 12:685370. PMC: 8248490. DOI: 10.3389/fimmu.2021.685370. View

Zhang F, Li F, Lu G, Nie W, Zhang L, Lv Y . Engineering Magnetosomes for Ferroptosis/Immunomodulation Synergism in Cancer. ACS Nano. 2019; 13(5):5662-5673. DOI: 10.1021/acsnano.9b00892. View

Luke J, Flaherty K, Ribas A, Long G . Targeted agents and immunotherapies: optimizing outcomes in melanoma. Nat Rev Clin Oncol. 2017; 14(8):463-482. DOI: 10.1038/nrclinonc.2017.43. View

Varn F, Tafe L, Amos C, Cheng C . Computational immune profiling in lung adenocarcinoma reveals reproducible prognostic associations with implications for immunotherapy. Oncoimmunology. 2018; 7(6):e1431084. PMC: 5980421. DOI: 10.1080/2162402X.2018.1431084. View

Tsoi J, Robert L, Paraiso K, Galvan C, Sheu K, Lay J . Multi-stage Differentiation Defines Melanoma Subtypes with Differential Vulnerability to Drug-Induced Iron-Dependent Oxidative Stress. Cancer Cell. 2018; 33(5):890-904.e5. PMC: 5953834. DOI: 10.1016/j.ccell.2018.03.017. View

Stockwell B, Friedmann Angeli J, Bayir H, Bush A, Conrad M, Dixon S . Ferroptosis: A Regulated Cell Death Nexus Linking Metabolism, Redox Biology, and Disease. Cell. 2017; 171(2):273-285. PMC: 5685180. DOI: 10.1016/j.cell.2017.09.021. View

10.

Kim T, Cui R, Jeon Y, Lee J, Lee J, Sim H . Long-range interaction and correlation between MYC enhancer and oncogenic long noncoding RNA CARLo-5. Proc Natl Acad Sci U S A. 2014; 111(11):4173-8. PMC: 3964128. DOI: 10.1073/pnas.1400350111. View

11.

Darmawan C, Jo G, Montenegro S, Kwak Y, Cheol L, Cho K . Early detection of acral melanoma: A review of clinical, dermoscopic, histopathologic, and molecular characteristics. J Am Acad Dermatol. 2019; 81(3):805-812. DOI: 10.1016/j.jaad.2019.01.081. View

12.

Prensner J, Zhao S, Erho N, Schipper M, Iyer M, Dhanasekaran S . RNA biomarkers associated with metastatic progression in prostate cancer: a multi-institutional high-throughput analysis of SChLAP1. Lancet Oncol. 2014; 15(13):1469-1480. PMC: 4559342. DOI: 10.1016/S1470-2045(14)71113-1. View

13.

Alqahtani S, Alhefdhi A, Almalik O, Anwar I, Mahmood R, Mahasin Z . Primary oral malignant melanoma metastasis to the brain and breast: A case report and literature review. Oncol Lett. 2017; 14(2):1275-1280. PMC: 5529946. DOI: 10.3892/ol.2017.6304. View

14.

Song X, Wang X, Liu Z, Yu Z . Role of GPX4-Mediated Ferroptosis in the Sensitivity of Triple Negative Breast Cancer Cells to Gefitinib. Front Oncol. 2021; 10:597434. PMC: 7785974. DOI: 10.3389/fonc.2020.597434. View

15.

Chen Y, Chang W, Lin E, Chen Y, Kuo P . Expressions of HLA Class II Genes in Cutaneous Melanoma Were Associated with Clinical Outcome: Bioinformatics Approaches and Systematic Analysis of Public Microarray and RNA-Seq Datasets. Diagnostics (Basel). 2019; 9(2). PMC: 6628136. DOI: 10.3390/diagnostics9020059. View

16.

Song W, Zhang J, Zhang J, Sun M, Xia Q . Overexpression of lncRNA PIK3CD-AS1 promotes expression of LATS1 by competitive binding with microRNA-566 to inhibit the growth, invasion and metastasis of hepatocellular carcinoma cells. Cancer Cell Int. 2019; 19:150. PMC: 6784333. DOI: 10.1186/s12935-019-0857-3. View

17.

Hung C, Wang L, Yu Y, Chen H, Srivastava S, Petrovics G . A long noncoding RNA connects c-Myc to tumor metabolism. Proc Natl Acad Sci U S A. 2014; 111(52):18697-702. PMC: 4284533. DOI: 10.1073/pnas.1415669112. View

18.

Guo W, Wang H, Yang Y, Guo S, Zhang W, Liu Y . Down-regulated miR-23a Contributes to the Metastasis of Cutaneous Melanoma by Promoting Autophagy. Theranostics. 2017; 7(8):2231-2249. PMC: 5505056. DOI: 10.7150/thno.18835. View

19.

Cursons J, Souza-Fonseca-Guimaraes F, Foroutan M, Anderson A, Hollande F, Hediyeh-Zadeh S . A Gene Signature Predicting Natural Killer Cell Infiltration and Improved Survival in Melanoma Patients. Cancer Immunol Res. 2019; 7(7):1162-1174. DOI: 10.1158/2326-6066.CIR-18-0500. View

20.

Jenkins R, Fisher D . Treatment of Advanced Melanoma in 2020 and Beyond. J Invest Dermatol. 2020; 141(1):23-31. PMC: 7541692. DOI: 10.1016/j.jid.2020.03.943. View